https://www.selleckchem.com/pe....ptide/gp91ds-tat.htm
Increased activity of STAT3 is associated with progression of head and neck squamous cell carcinoma (HNSCC). Upstream activators of STAT3, such as JAKs, represent potential targets for therapy of solid tumors, including HNSCC. In this study, we investigated the anticancer effects of ruxolitinib, a clinical JAK1/2 inhibitor, in HNSCC preclinical models, including patient-derived xenografts (PDX) from patients treated on a window-of-opportunity trial. HNSCC cell lines were treated with ruxolitinib, and the impact on activated STAT3 leve
Like
Comment
Share
